Ken Lee

Director, Bioprocess Technologies and Engineering, BioPharmaceuticals Development, R&D at AstraZeneca

Speaker

Ken received his PhD from the University of Birmingham, UK, in Chemical Engineering in 2009, after which he took up a position at TAP Biosystems, now Sartorius, as a development engineer on the ambr15 fed-batch workstation. He then joined AstraZeneca in 2011 and has been working as part of the cell culture bioreactor development team in Cambridge, UK then in Gaithersburg, US primarily on early phase projects. In 2020 Ken took an internal move to lead the Upstream Continuous Processing Platform team. As part of this role Ken was able to bring recirculating loop perfusion to AstraZeneca and demonstrate a robust and scalable process from ambr250 to 50L